<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benefits and risks of three versus six months of adjuvant oxaliplatin-containing chemotherapy in patients with high-risk stage II colon cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benefits and risks of three versus six months of adjuvant oxaliplatin-containing chemotherapy in patients with high-risk stage II colon cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Benefits and risks of three versus six months of adjuvant oxaliplatin-containing chemotherapy in patients with high-risk stage II colon cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup span="2" width="10%"></colgroup><colgroup span="2" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Outcome</td> <td class="subtitle1" rowspan="2">Results</td> <td class="subtitle1" colspan="2">Absolute effect estimates</td> <td class="subtitle1" rowspan="2">Quality of evidence</td> <td class="subtitle1" rowspan="2">Plain language summary</td> </tr> <tr> <td class="subtitle2">6-Month ADCT</td> <td class="subtitle2">3-Month ADCT</td> </tr> <tr> <td class="divider_bottom" rowspan="2">DFS (overall study population)</td> <td class="divider_bottom" rowspan="2">HR: 1.17 (80% CI, 1.05 to 1.31)<br/> (95% CI, 0.99 to 1.38)<br/> (3273 patients in four studies*)<br/> Follow-up: 5 years</td> <td>161 per 1000</td> <td>186 per 1000</td> <td class="divider_bottom" rowspan="2">Low<sup>¶</sup></td> <td class="divider_bottom" rowspan="2">3-Month ADCT probably has little or no effect on DFS compared with 6-month ADCT</td> </tr> <tr class="divider_bottom"> <td colspan="2">Difference: 25 more per 1000 (95% CI, 7 more to 44 more)</td> </tr> <tr> <td class="divider_bottom" rowspan="2">DFS (CAPOX)</td> <td class="divider_bottom" rowspan="2">HR: 1.02 (80% CI, 0.88 to 1.17)<br/> (95% CI, 0.83 to 1.28)<br/> (2019 patients in four studies*)<br/> Follow-up: 5 years</td> <td>159 per 1000</td> <td>162 per 1000</td> <td class="divider_bottom" rowspan="2">Low<sup>¶</sup></td> <td class="divider_bottom" rowspan="2">3-month ADCT probably has little or no effect on DFS (CAPOX) compared with 6-month ADCT</td> </tr> <tr class="divider_bottom"> <td colspan="2">Difference: 3 more per 1000 (95% CI, 18 fewer to 24 more)</td> </tr> <tr> <td class="divider_bottom" rowspan="2">DFS (FOLFOX)</td> <td class="divider_bottom" rowspan="2">HR: 1.41 (80% CI, 1.18 to 1.68)<br/> (95% CI, 1.08 to 1.84)<br/> (1254 patients in four studies*)<br/> Follow-up: 5 years</td> <td>150 per 1000</td> <td>205 per 1000</td> <td class="divider_bottom" rowspan="2">Low<sup>¶</sup></td> <td class="divider_bottom" rowspan="2">3-month ADCT probably worsens DFS (FOLFOX) compared with 6-month ADCT</td> </tr> <tr class="divider_bottom"> <td colspan="2">Difference: 55 more per 1000 (95% CI, 25 more to 89 more)</td> </tr> <tr> <td rowspan="2">Grade ≥2 peripheral neuropathy</td> <td rowspan="2">RR: 0.36 (95% CI, 0.31 to 0.42)<br/> (3273 patients in four studies*)<br/> Follow-up during treatment</td> <td>360 per 1000</td> <td>130 per 1000</td> <td rowspan="2">Moderate</td> <td rowspan="2">Patients experience significantly less peripheral neuropathy with 3 months of ADCT compared with 6 months of ADCT</td> </tr> <tr> <td colspan="2">Difference: 230 fewer per 1000 (95% CI, 248 fewer to 209 fewer)</td> </tr> </tbody></table></div><div class="graphic_footnotes">ADCT: adjuvant doublet chemotherapy; 
	DFS: disease-free survival; 
	HR: hazard ratio; 
	CAPOX: capecitabine and oxaliplatin; 
	FOLFOX: fluorouracil, leucovorin, and oxaliplatin; 
	RR: relative risk; 
	SCOT: Short Course Oncology Treatment; 
	ACHIEVE2: Adjuvant Chemotherapy for Colon Cancer with High Evidence 2; 
	TOSCA: Three or Six Colon Adjuvant; 
	HORG: Hellenic Oncology Research Group.<br/>
	
	* SCOT (NCT00749450), ACHIEVE2 (UMIN000013036), TOSCA (NCT0064660), and HORG (NCT01308086).<br/>
		
	¶ Choice of CAPOX or FOLFOX was nonrandomized (chosen by treating clinician); noninferiority threshold of 1.2 not met; modified intention-to-treat analysis including only patients who received at least one dose of chemotherapy. Ninety% of patients assigned to 3-month treatment received all planned doses, compared with 65% of 6-month patients. Analyses by T4 (yes or no), inadequate nodal harvest (yes or no), and poorly differentiated histology (yes or no) were not significant. Test for interaction between duration and the regimen was not significant (p = 0.07); adjusted for multiple hypothesis tests.</div><div class="graphic_reference">From: Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol 2021. DOI: <a href="https://ascopubs.org/doi/pdf/10.1200/JCO.21.02538" target="_blank">10.1200/JCO.21.02538</a>. Copyright © 2021 American Society of Clinical Oncology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 134892 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
